Cargando…

Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study

OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold s...

Descripción completa

Detalles Bibliográficos
Autores principales: Skopalik, Josef, Polakova, Katerina, Havrdova, Marketa, Justan, Ivan, Magro, Massimiliano, Milde, David, Knopfova, Lucia, Smarda, Jan, Polakova, Helena, Gabrielova, Eva, Vianello, Fabio, Michalek, Jaroslav, Zboril, Radek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245086/
https://www.ncbi.nlm.nih.gov/pubmed/25484583
http://dx.doi.org/10.2147/IJN.S66986
_version_ 1782346307057221632
author Skopalik, Josef
Polakova, Katerina
Havrdova, Marketa
Justan, Ivan
Magro, Massimiliano
Milde, David
Knopfova, Lucia
Smarda, Jan
Polakova, Helena
Gabrielova, Eva
Vianello, Fabio
Michalek, Jaroslav
Zboril, Radek
author_facet Skopalik, Josef
Polakova, Katerina
Havrdova, Marketa
Justan, Ivan
Magro, Massimiliano
Milde, David
Knopfova, Lucia
Smarda, Jan
Polakova, Helena
Gabrielova, Eva
Vianello, Fabio
Michalek, Jaroslav
Zboril, Radek
author_sort Skopalik, Josef
collection PubMed
description OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold standard for the labeling of the MSCs for magnetic resonance imaging (MRI) is available yet. This work evaluates our newly synthesized uncoated superparamagnetic maghemite nanoparticles (surface-active maghemite nanoparticles – SAMNs) as an MRI contrast intracellular probe usable in a clinical 1.5 T MRI system. METHODS: MSCs from rat and human donors were isolated, and then incubated at different concentrations (10–200 μg/mL) of SAMN maghemite nanoparticles for 48 hours. Viability, proliferation, and nanoparticle uptake efficiency were tested (using fluorescence microscopy, xCELLigence analysis, atomic absorption spectroscopy, and advanced microscopy techniques). Migration capacity, cluster of differentiation markers, effect of nanoparticles on long-term viability, contrast properties in MRI, and cocultivation of labeled cells with myocytes were also studied. RESULTS: SAMNs do not affect MSC viability if the concentration does not exceed 100 μg ferumoxide/mL, and this concentration does not alter their cell phenotype and long-term proliferation profile. After 48 hours of incubation, MSCs labeled with SAMNs show more than double the amount of iron per cell compared to Resovist-labeled cells, which correlates well with the better contrast properties of the SAMN cell sample in T2-weighted MRI. SAMN-labeled MSCs display strong adherence and excellent elasticity in a beating myocyte culture for a minimum of 7 days. CONCLUSION: Detailed in vitro tests and phantom tests on ex vivo tissue show that the new SAMNs are efficient MRI contrast agent probes with exclusive intracellular uptake and high biological safety.
format Online
Article
Text
id pubmed-4245086
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42450862014-12-05 Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study Skopalik, Josef Polakova, Katerina Havrdova, Marketa Justan, Ivan Magro, Massimiliano Milde, David Knopfova, Lucia Smarda, Jan Polakova, Helena Gabrielova, Eva Vianello, Fabio Michalek, Jaroslav Zboril, Radek Int J Nanomedicine Original Research OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold standard for the labeling of the MSCs for magnetic resonance imaging (MRI) is available yet. This work evaluates our newly synthesized uncoated superparamagnetic maghemite nanoparticles (surface-active maghemite nanoparticles – SAMNs) as an MRI contrast intracellular probe usable in a clinical 1.5 T MRI system. METHODS: MSCs from rat and human donors were isolated, and then incubated at different concentrations (10–200 μg/mL) of SAMN maghemite nanoparticles for 48 hours. Viability, proliferation, and nanoparticle uptake efficiency were tested (using fluorescence microscopy, xCELLigence analysis, atomic absorption spectroscopy, and advanced microscopy techniques). Migration capacity, cluster of differentiation markers, effect of nanoparticles on long-term viability, contrast properties in MRI, and cocultivation of labeled cells with myocytes were also studied. RESULTS: SAMNs do not affect MSC viability if the concentration does not exceed 100 μg ferumoxide/mL, and this concentration does not alter their cell phenotype and long-term proliferation profile. After 48 hours of incubation, MSCs labeled with SAMNs show more than double the amount of iron per cell compared to Resovist-labeled cells, which correlates well with the better contrast properties of the SAMN cell sample in T2-weighted MRI. SAMN-labeled MSCs display strong adherence and excellent elasticity in a beating myocyte culture for a minimum of 7 days. CONCLUSION: Detailed in vitro tests and phantom tests on ex vivo tissue show that the new SAMNs are efficient MRI contrast agent probes with exclusive intracellular uptake and high biological safety. Dove Medical Press 2014-11-20 /pmc/articles/PMC4245086/ /pubmed/25484583 http://dx.doi.org/10.2147/IJN.S66986 Text en © 2014 Skopalik et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Skopalik, Josef
Polakova, Katerina
Havrdova, Marketa
Justan, Ivan
Magro, Massimiliano
Milde, David
Knopfova, Lucia
Smarda, Jan
Polakova, Helena
Gabrielova, Eva
Vianello, Fabio
Michalek, Jaroslav
Zboril, Radek
Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title_full Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title_fullStr Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title_full_unstemmed Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title_short Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
title_sort mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial resovist – an initial in vitro study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245086/
https://www.ncbi.nlm.nih.gov/pubmed/25484583
http://dx.doi.org/10.2147/IJN.S66986
work_keys_str_mv AT skopalikjosef mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT polakovakaterina mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT havrdovamarketa mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT justanivan mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT magromassimiliano mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT mildedavid mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT knopfovalucia mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT smardajan mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT polakovahelena mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT gabrielovaeva mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT vianellofabio mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT michalekjaroslav mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy
AT zborilradek mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy